Search

Unlabelled: A challenge in biodata analysis is to understand the underlying phenomena among many interactions in signaling pathways. Such study is formulated as the pathway enrichment analysis, which identifies relevant pathways functional enriched in high-throughput data. The question faced here is how to analyze different data types in a unified and integrative way by characterizing pathways that these data simultaneously reveal. To this end, we developed integrative Pathway Enrichment Analysis Platform, iPEAP, which handles transcriptomics, proteomics, metabolomics and GWAS data under a unified aggregation schema. iPEAP emphasizes on the ability to aggregate various pathway enrichment results generated in different high-throughput experiments, as well as the quantitative measurements of different ranking results, thus providing the first benchmark platform for integration, comparison and evaluation of multiple types of data and enrichment methods., Availability and Implementation: iPEAP is freely available at http://www.tongji.edu.cn/∼qiliu/ipeap.html.

HIV-1 protease is one of the main therapeutic targets in HIV. However, a major problem in treatment of HIV is the rapid emergence of drug-resistant strains. It should be particularly helpful to clinical therapy of AIDS if one method can be used to predict antivirus capability of compounds for different variants. In our study, proteochemometric (PCM) models were created to study the bioactivity spectra of 92 chemical compounds with 47 unique HIV-1 protease variants. In contrast to other PCM models, which used Multiplication of Ligands and Proteins Descriptors (MLPD) as cross-term, one new cross-term, i.e. Protein-Ligand Interaction Fingerprint (PLIF) was introduced in our modeling. With different combinations of ligand descriptors, protein descriptors and cross-terms, nine PCM models were obtained, and six of them achieved good predictive abilities (Q(2)(test)>0.7). These results showed that the performance of PCM models could be improved when ligand and protein descriptors were complemented by the newly introduced cross-term PLIF. Compared with the conventional cross-term MLPD, the newly introduced PLIF had a better predictive ability. Furthermore, our best model (GD & P & PLIF: Q(2)(test) = 0.8271) could select out those inhibitors which have a broad antiviral activity. As a conclusion, our study indicates that proteochemometric modeling with PLIF as cross-term is a potential useful way to solve the HIV-1 drug-resistant problem.

Abstract: G protein-coupled receptors (GPCRs) are the most frequently addressed drug targets in the pharmaceutical industry. However, achieving highly safety and efficacy in designing of GPCR drugs is quite challenging since their primary amino acid sequences show fairly high homology. Systematic study on the interaction spectra of inhibitors with multiple human GPCRs will shed light on how to design the inhibitors for different diseases which are related to GPCRs. To reach this goal, several proteochemometric models were constructed based on different combinations of two protein descriptors, two ligand descriptors and one ligand–receptor cross-term by two kinds of statistical learning techniques. Our results show that support vector regression (SVR) performs better than Gaussian processes (GP) for most combinations of descriptors. The transmembrane (TM) identity descriptors have more powerful ability than the z-scale descriptors in the characterization of GPCRs. Furthermore, the performance of our PCM models was not improved by introducing the cross-terms. Finally, based on the TM Identity descriptors and 28-dimensional drug-like index, two best PCM models with GP and SVR (GP-S-DLI: R 2 =0.9345, Q 2 test =0.7441; SVR-S-DLI: R 2 =1.0000, Q 2 test =0.7423) were derived respectively. The area of ROC curve was 0.8940 when an external test set was used, which indicates that our PCM model obtained a powerful capability for predicting new interactions between GPCRs and ligands. Our results indicate that the derived best model has a high predictive ability for human GPCR–inhibitor interactions. It can be potentially used to discover novel multi-target or specific inhibitors of GPCRs with higher efficacy and fewer side effects. [Copyright &y& Elsevier]